# Palmitoylethanolamide (PEA) regulates cell cycle progression and promotes an anti‐inflammatory transcriptomic signature in C2C12 skeletal muscle cells

**Authors:** Paige L. Cole, Scott H. Gillham, Mark R. Viggars, Graeme L. Close, Daniel J. Owens

PMC · DOI: 10.14814/phy2.70780 · 2026-02-15

## TL;DR

This study shows that PEA affects muscle cell growth and reduces inflammation, suggesting potential benefits for muscle health.

## Contribution

The study reveals PEA's novel role in regulating muscle cell cycle and inducing an anti-inflammatory gene expression profile.

## Key findings

- PEA reduces myotube number but increases nuclear fusion in muscle cells.
- PEA induces G1 cell cycle arrest in myoblasts.
- PEA alters gene expression, promoting an anti-inflammatory immune profile.

## Abstract

Palmitoylethanolamide (PEA) is an endogenous lipid mediator with immunomodulatory actions, yet its effects in skeletal muscle remain poorly defined. We examined whether PEA influences myogenesis and profiled the acute transcriptomic response of differentiated C2C12 myotubes to 10 μM PEA. PEA decreased myotube number (90.3 ± 10.6 vs. 112.6 ± 10.1 control) while increasing nuclear fusion index (37.8 ± 5.7% vs. 30.7 ± 3.2%); myotube area was unchanged. In myoblasts, 24 h PEA increased G0/G1 (48.2 ± 1.2% vs. 42.3 ± 1.9%) and reduced S‐phase (21.7 ± 1.2% vs. 25.5 ± 1.2%), consistent with G1 arrest. RNA sequencing identified 1952 differentially expressed genes enriched for cytokine–receptor interactions and inflammatory signaling. PEA downregulated NF‐κB target cytokines while upregulating interferon‐related and chemokine genes, indicating an anti‐inflammatory/immune‐priming profile. N‐acylethanolamine acid amidase was highly expressed and induced, whereas fatty acid amide hydrolase remained low and unchanged, suggesting muscle‐specific reliance on NAAA metabolism. These data show that PEA biases skeletal muscle toward a less proliferative but more fused and inflammation‐resolving phenotype, with transcriptional reprogramming of immune pathways and preferential NAAA engagement. These findings motivate in vivo studies to test whether such actions benefit muscle regeneration, adaptation, or anti‐atrophy interventions.

## Linked entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** Palmitoylethanolamide (PubChem CID 4671)

## Full-text entities

- **Genes:** Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Dnah8 (dynein, axonemal, heavy chain 8) [NCBI Gene 13417] {aka ATPase, Dnahc8, Hst6.7b, P1-Loop}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, trypsin [NCBI Gene 100769881], Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Napepld (N-acyl phosphatidylethanolamine phospholipase D) [NCBI Gene 242864] {aka A530089G06, Mbldc1, NAPE-PLD}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, Cxcl14 (C-X-C motif chemokine ligand 14) [NCBI Gene 57266] {aka 1110031L23Rik, 1200006I23Rik, BMAC, BRAK, KS1, Kec}, MPO (myeloperoxidase) [NCBI Gene 4353], Il33 (interleukin 33) [NCBI Gene 77125] {aka 9230117N10Rik, Il-33, Il1f11, NF-HEV}, Ccnd1 (cyclin D1) [NCBI Gene 12443] {aka CycD1, Cyl-1, PRAD1, bcl-1, cD1}, Gpr55 (G protein-coupled receptor 55) [NCBI Gene 227326] {aka CTFL, Gm218, Lpir1}, Cdk2 (cyclin dependent kinase 2) [NCBI Gene 12566] {aka A630093N05Rik}, Oas1b (2'-5' oligoadenylate synthetase 1B) [NCBI Gene 23961] {aka Flv, L1, Mmu-L1, Oas1, Oias-2, Oias2}, Gbp7 (guanylate binding protein 7) [NCBI Gene 229900] {aka 9830147J24Rik, GBP-7}, Socs1 (suppressor of cytokine signaling 1) [NCBI Gene 12703] {aka Cish1, Cish7, JAB, SOCS-1, SSI-1}, Stat2 (signal transducer and activator of transcription 2) [NCBI Gene 20847] {aka 1600010G07Rik}, Rnase1 (ribonuclease, RNase A family, 1 (pancreatic)) [NCBI Gene 19752] {aka Rib-1, Rib1}, Cdk4 (cyclin dependent kinase 4) [NCBI Gene 12567] {aka Crk3}, Tnfrsf19 (tumor necrosis factor receptor superfamily, member 19) [NCBI Gene 29820] {aka TAJ, TAJ-ALPHA, TRADE, Troy}, Naaa (N-acylethanolamine acid amidase) [NCBI Gene 67111] {aka 2210023K21Rik, 3830414F09Rik, Asahl}, Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Faah (fatty acid amide hydrolase) [NCBI Gene 14073], Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Il12a (interleukin 12a) [NCBI Gene 16159] {aka IL-12p35, Il-12a, Ll12a, p35}
- **Diseases:** muscle atrophy (MESH:D009133), inflammation (MESH:D007249), sarcopenia (MESH:D055948), neurodegeneration (MESH:D019636), disease (MESH:D004194), pain (MESH:D010146), oedema (MESH:C536897), atrophy (MESH:D001284), neuroinflammation (MESH:D000090862), cytotoxicity (MESH:D064420), chronic pain conditions (MESH:D059350), obese (MESH:D009765), neuropathic pain (MESH:D009437), musculoskeletal disorders (MESH:D009140), basophilic leukemia (MESH:D015471), muscle disorders (MESH:D009135), EIMD (MESH:D000092202), colon adenocarcinoma (MESH:D003110), PLC (MESH:C537875)
- **Chemicals:** 2-AG (MESH:C094503), 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MESH:C022616), ethanolamine (MESH:D019856), H2O2 (MESH:D006861), PI (MESH:D011419), N-palmitoyl-phosphatidylethanolamine (MESH:C067565), DMEM (-), formazan (MESH:D005562), carrageenan (MESH:D002351), N-acylethanolamines (MESH:C022203), penicillin (MESH:D010406), Levagen + (MESH:C005958), MTT (MESH:C070243), GW7647 (MESH:C453899), EDTA (MESH:D004492), fatty acid (MESH:D005227), Alexa-Fluor 488 (MESH:C000711379), WY-14,643 (MESH:C006253), streptomycin (MESH:D013307), Triton X-100 (MESH:D017830), CO2 (MESH:D002245), H2O (MESH:D014867), tetrazolium (MESH:D013778), FL (MESH:D005459), endocannabinoid (MESH:D063388), lipid (MESH:D008055), cysteine (MESH:D003545), paraformaldehyde (MESH:C003043), NBCS (MESH:D009675), LPS (MESH:D008070), palmitic acid (MESH:D019308), nitrotyrosine (MESH:C002744), anandamide (MESH:C078814), HS (MESH:D006859), PBS (MESH:D007854), 4',6-diamidino-2-phenylindole (MESH:C007293), DMSO (MESH:D004121), ethanol (MESH:D000431)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Musculus (genus) [taxon 112137]
- **Cell lines:** muscle — Rattus norvegicus (Rat), Finite cell line (CVCL_XB60), RBL-2H3 — Rattus norvegicus (Rat), Rat leukemia, Cancer cell line (CVCL_0591), C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188), FL-3 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_M897), N9 — Mus musculus (Mouse), Transformed cell line (CVCL_0452)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907578/full.md

---
Source: https://tomesphere.com/paper/PMC12907578